A 37-year-old named Ed Hunt rolled up his sleeve in Oxford last week — and became part of medical history.
He's the first human ever to receive a vaccine against Bundibugyo ebolavirus.
A strain of Ebola that, until now, had zero approved shots protecting against it.
Let that sink in.
We've had vaccines for other Ebola strains since 2019.
Bundibugyo? Left out. Until today.
It's an old friend, repurposed.
The jab — called ChAdOx1 BDBV — runs on the exact same viral vector tech as the Oxford/AstraZeneca COVID vaccine.
Yes. The one that helped vaccinate billions between 2020 and 2023.
Scientists just swapped the payload.
Same chassis. Different cargo. New enemy.
Because the world can't afford to wait anymore.
👉 The Democratic Republic of Congo is currently battling an intensifying Ebola outbreak
👉 Bundibugyo ebolavirus was first identified in Uganda in 2007 — and has quietly stayed unprotected for nearly two decades
👉 CEPI (the Coalition for Epidemic Preparedness Innovations) is backing this with an $8.6 million program
👉 Oxford's Pandemic Sciences Institute is running it alongside the Serum Institute of India — the world's biggest vaccine maker
This is just Phase I.
50 healthy adults, aged 18 to 55, will get the shot over the coming months.
No efficacy claims yet — just safety and immune response, the first real checkpoint every vaccine has to clear.
Slow. Careful. Exactly how it should be.
But here's the bigger story hiding underneath.
The COVID vaccine wasn't just a one-time win.
It built a platform — one that scientists can now point at new threats and fire quickly.
Ebola today.
Who knows what tomorrow.
That's the real legacy of 2020 — not just the vaccine we got, but the machine we built to make the next one faster.
That's all for now!
